摘要

Authors' objectives: BACKGROUND: Subclinical hypothyroidism (SCH) is a hormonal disorder in which the serum thyroid-stimulating hormone levels (TSH) are elevated while the thyroid hormone levels are within the normal reference range. SCH can be treated with hormone replacement therapy using levothyroxine, a synthetic version of the endogenous thyroid hormone thyroxine (T4), to raise low levels of endogenous thyroid hormones. In Switzerland, levothyroxine is approved by the Swiss Agency for Therapeutic Products (Swissmedic) for the treatment of hypothyroidism. There is no standard alternative treatment option for patients diagnosed with SCH. OBJECTIVE: The aim of this health technology assessment (HTA) report is to evaluate the clinical and economic consequences of levothyroxine treatment for patients diagnosed with SCH in Switzerland.